Prognostic value of NF-κB interacting long non-coding RNA expression in lung adenocarcinoma and lung squamous cell cancer: a study based on the cancer genome atlas datasets

2018 ◽  
Vol 7 (1) ◽  
pp. 109-120
Author(s):  
Bohua Fu ◽  
Yuzhu Xu ◽  
Yi Wang ◽  
Huilong Chen ◽  
Zhenli Huang ◽  
...  
2021 ◽  
Author(s):  
Guofei Zhang ◽  
Jiayi Shen ◽  
Zipu Yu ◽  
Gang Shen ◽  
Chengxiao Liang

Abstract BackgroundEvidence suggests that long non-coding RNAs (lncRNAs) are involved in various cancers. Here, we developed and evaluated an autophagy-related prognostic lncRNA signature for lung adenocarcinoma (LUAD). ResultsUsing a publicly available microarray dataset from The Cancer Genome Atlas, we analyzed the lncRNA expression profile in a cohort of 439 LUAD patients. The lncRNA-mRNA co-expression network along with univariate and multivariate Cox regression analyses were used to determine 15 autophagy-related lncRNA signatures that were significantly correlated with patient overall survival. Autophagy-related lncRNA signatures stratified patients into high- and low-risk groups with significantly different survival (hazard ratio = 3.256, 95% confidence interval = 2.858–4.101, P < 0.001). The lncRNA signature was further confirmed in other independent datasets. Moreover, the lncRNA signature had prognostic value independent of routine clinical factors. Functional analysis indicated that autophagy-related lncRNA signatures may be involved in LUAD via known autophagy-related pathways. ConclusionsThis newly identified autophagy-related lncRNA signature is a more powerful prognostic tool than the clinicopathological factors routinely used to predict patient survival, and can provide further insights into the molecular mechanisms underlying LUAD.


2017 ◽  
Vol 41 (4) ◽  
pp. 1468-1480 ◽  
Author(s):  
Yingjie Shao ◽  
Wendong Gu ◽  
Zhonghua Ning ◽  
Xing Song ◽  
Honglei Pei ◽  
...  

Background: It has been reported that miR-203 expression was aberrant in various types of cancers, and it could be used as a prognostic biomarker. Therefore, in this study, we aimed to evaluate the prognostic value of miR-203 expression in solid tumors by using meta-analysis and The Cancer Genome Atlas (TCGA) datasets. Methods: By doing a literature research in PubMed, Embase and the Cochrane Library (last update by December 2016), we were able to identify the studies assessing the prognostic role of miR-203 in various tumors. We then used TCGA datasets to validate the results of meta-analysis. Results:33 studies from 26 articles were qualified and enrolled in this meta-analysis. Pooled analyses showed that higher expression of miR-203 in tissues couldn’t predict poor overall survival (OS) and progression-free survival (PFS) in solid tumors. However, the results of subgroup analyses revealed that the upregulation of tissue miR-203 expression was associated with poor OS in colorectal cancer (hazard ratio (HR)=1.81, 95% confidence intervals (CI) 1.31-2.49; P<0.001), pancreatic cancer (HR=1.19, 95% CI 1.09-1.31; P<0.001) and ovarian cancer (HR=1.85, 95% CI 1.45-2.37; P<0.001); but it had opposite association in liver cancer (HR=0.52, 95% CI 0.28-0.97; P=0.040) and esophageal cancer (HR=0.41, 95% CI 0.25-0.66; P<0.001). Based on TCGA datasets, we found the same results for pancreatic cancer and esophageal cancer, but not for colorectal cancer and liver cancer. Moreover, patients with high circulating miR-203 in blood had significantly poor OS and PFS in colorectal cancer and breast cancer. Conclusion: Our study showed that the prognostic values of tissue miR-203 varied in different tumor types. In addition, the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer.


2020 ◽  
Author(s):  
Yingtong Wu ◽  
Ning Chang ◽  
Yong Zhang ◽  
Xinxin Zhang ◽  
Leidi Xu ◽  
...  

Abstract BackgroundFBXW7 m6A modification plays an important role in lung adenocarcinoma (LUAD) progression; however, the underlying mechanisms remain unclear.MethodsThe correlation between FBXW7 and various genes related to m6A modification was analyzed using The Cancer Genome Atlas database. The regulatory effects of METTL3 on FBXW7 mRNA m6A modification were examined in a cell model, and the underlying mechanism was determined by methylated RNA immunoprecipitation, RNA immunoprecipitation, luciferase reporter, and mutagenesis assays. In vitro experiments were performed to further explore the biological effects of METTL3-mediated FBXW7 m6A modification on LUAD development.ResultsDecreased FBXW7 expression was accompanied by downregulated METTL3 expression in human LUAD tissues and was associated with a worse prognosis for LUAD in The Cancer Genome Atlas database. m6A was highly enriched in METTL3-mediated FBXW7 transcripts, and increased m6A modification in the coding sequence region increased its translation. Functionally, METTL3 overexpression or knockdown affected the apoptosis and proliferation phenotype of LUAD cells by regulating FBXW7 m6A modification and expression. Furthermore, FBXW7 overexpression in METTL3-depleted cells partially restored the suppression of LUAD cells in vitro and in vivo.ConclusionsOur findings reveal that METTL3 positively regulates FBXW7 expression and confirm the tumor-suppressive role of m6A-modified FBXW7, thus providing insight into its epigenetic regulatory mechanisms in LUAD initiation and development.


2021 ◽  
Vol 12 (18) ◽  
pp. 5506-5518
Author(s):  
Yi-Zhen Gong ◽  
Hui Ma ◽  
Guo-Tian Ruan ◽  
Li-Chen Zhu ◽  
Xi-Wen Liao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document